Literature DB >> 35718818

Reciprocal regulation of Daxx and PIK3CA promotes colorectal cancer cell growth.

Yen-Sung Huang1,2, Chang-Chieh Wu3, Che-Chang Chang4,5,6,7, Shiu-Feng Huang8, Hong-Yi Kuo8, Hsiu-Ming Shih9,10,11.   

Abstract

Upregulation of death-domain-associated protein (Daxx) is strongly associated with diverse cancer types. Among these, the clinicopathological significance and molecular mechanisms of Daxx overexpression in colorectal cancer (CRC) remain unknown. Here, we showed that Daxx expression was increased in both clinical CRC samples and CRC cell lines. Daxx knockdown significantly reduced proliferation activity in CRC cells and tumor growth in a xenograft model. Further studies revealed that Daxx expression could be attenuated by either treatment with the PIK3CA inhibitor PIK-75 or PIK3CA depletion in CRC cells. Conversely, expression of PIK3CA constitutively active mutants could increase Daxx expression. These data suggest that PIK3CA positively regulates Daxx expression. Consistently, the expression levels of PIK3CA and Daxx were positively correlated in sporadic CRC samples. Interestingly, Daxx knockdown or overexpression yielded decreased or increased levels of PIK3CA, respectively, in CRC cells. We further demonstrated that Daxx activates the promoter activity and expression of PIK3CA. Altogether, our results identify a mechanistic pathway of Daxx overexpression in CRC and suggest a reciprocal regulation between Daxx and PIK3CA for CRC cell growth.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  AKT; CRC; PI3K inhibitors; PIK3CA; p110α

Mesh:

Substances:

Year:  2022        PMID: 35718818     DOI: 10.1007/s00018-022-04399-8

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.207


  44 in total

Review 1.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 2.  The role of the PI3K pathway in colorectal cancer.

Authors:  Dionysios Papadatos-Pastos; Roy Rabbie; Paul Ross; Debashis Sarker
Journal:  Crit Rev Oncol Hematol       Date:  2014-12-25       Impact factor: 6.312

Review 3.  Portrait of the PI3K/AKT pathway in colorectal cancer.

Authors:  Stine Aske Danielsen; Peter Wold Eide; Arild Nesbakken; Tormod Guren; Edward Leithe; Ragnhild A Lothe
Journal:  Biochim Biophys Acta       Date:  2014-11-22

4.  The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1.

Authors:  A Astanehe; M R Finkbeiner; P Hojabrpour; K To; A Fotovati; A Shadeo; A L Stratford; W L Lam; I M Berquin; V Duronio; S E Dunn
Journal:  Oncogene       Date:  2009-05-11       Impact factor: 9.867

5.  The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression.

Authors:  Rosaline C-Y Hui; Ana R Gomes; Demetra Constantinidou; Joana R Costa; Christina T Karadedou; Silvia Fernandez de Mattos; Matthias P Wymann; Jan J Brosens; Almut Schulze; Eric W-F Lam
Journal:  Mol Cell Biol       Date:  2008-07-21       Impact factor: 4.272

Review 6.  PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.

Authors:  Giovanni Ligresti; Loredana Militello; Linda S Steelman; Andrea Cavallaro; Francesco Basile; Ferdinando Nicoletti; Franca Stivala; James A McCubrey; Massimo Libra
Journal:  Cell Cycle       Date:  2009-05-23       Impact factor: 4.534

7.  Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment.

Authors:  Nuo Yang; Jia Huang; Joel Greshock; Shun Liang; Andrea Barchetti; Kosei Hasegawa; Sarah Kim; Antonis Giannakakis; Chunsheng Li; Anne O'Brien-Jenkins; Dionyssios Katsaros; Ralf Bützow; George Coukos; Lin Zhang
Journal:  PLoS One       Date:  2008-03-12       Impact factor: 3.240

8.  PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1.

Authors:  A M Ishov; A G Sotnikov; D Negorev; O V Vladimirova; N Neff; T Kamitani; E T Yeh; J F Strauss; G G Maul
Journal:  J Cell Biol       Date:  1999-10-18       Impact factor: 10.539

Review 9.  PI3K inhibitors are finally coming of age.

Authors:  Bart Vanhaesebroeck; Matthew W D Perry; Jennifer R Brown; Fabrice André; Klaus Okkenhaug
Journal:  Nat Rev Drug Discov       Date:  2021-06-14       Impact factor: 112.288

Review 10.  PIK3CA in Colorectal Cancer.

Authors:  Gieri Cathomas
Journal:  Front Oncol       Date:  2014-03-03       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.